Why Hypoestoxide is the Ideal Candidate Drug for Disease Modifying Treatment of Parkinson’s Disease

Emmanuel A. Ojo-Amaize* and Howard B. Cottam

*Correspondence: Emmanuel A. Ojo-Amaize, Immune Modulation, Inc., P.O. Box 998, Bloomington, CA 92316-0998, USA, Tel: 951-733-6787.


ABSTRACT

Parkinson’s disease (PD) is an idiopathic, relentlessly progressive neurodegenerative and chronic inflammatory disease caused by the accumulation of pathologic α-synuclein leading to neuronal death by apoptosis/mitophagy, chronic inflammation, abnormal calcium transport into cells and oxidative damage. Hypoestoxide (HE), is a natural diterpene extracted and purified from the Nigerian shrub Hypoestes rosea (Acanthaceae). HE has been shown to induce apoptosis, inhibit nuclear factor kappa B (NF-κB) activation leading to the inhibition of the production of pro-inflammatory cytokines (TNF-α, IL-1β and IL-6), inhibit oxidative damage via the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway which is a transcription factor that induces anti-oxidant response genes, activate Peroxisome proliferator-activated receptor-γ (PPAR-γ) leading to enhanced apoptosis and autophagy/mitophagy and inhibit α-synuclein accumulation. The accumulation of pathologic α-synuclein is said to be the eventual cause of neuronal death. These various molecular targets make HE an ideal candidate drug for eliminating the underlying cause and pathological features of PD.

Keywords
Parkinson’s disease, Hypoestoxide, Alzheimer’s disease.

Introduction
In the elderly population, PD is the second most common progressive neurodegenerative, chronic inflammatory incurable disorder after Alzheimer’s disease. While the underlying mechanisms of PD are still poorly understood, it is believed that the progressive nature of PD is driven by chronic inflammation-induced neurodegeneration of dopamine producing neurons within the substantia nigra (SN) and striatum [1-3].

Hypoestoxide (HE) is a novel, natural, non-synthesizable, non-toxic, and potent non-steroidal anti-inflammatory drug (NSAID). While HE is primarily a NSAID [4], it has other biological activities such as anti-cancer [5], anti-parasitic [6] and anti-viral [7]. HE is the major active pharmaceutical ingredient (API) of the Nigerian shrub Hypoestes rosea (Acanthaceae) [4]. Interestingly, the consumption of the dried leaf powder of this shrub as a daily dietary supplement [sold as “Peko-D”: NAFDAC REG. NO. A7-1913L] immensely improves the quality of life of PD patients in Nigeria.

HE has several molecular targets, which include but not limited to the following: NF-κB, Nrf2/ARE, PPAR-γ, α-synuclein. Each one of these targets will be discussed in relation to PD respectively.

Discussion

NF-κB, PD and HE
PD is a neurodegenerative condition, which is primarily driven by chronic inflammation. NF-κB is a family of inducible transcription factors that are expressed in a wide variety of cells and tissues, including microglia, astrocytes and neurons. This pathway plays an important role in the activation and regulation of pro-inflammatory cytokines’ production during the process of inflammation.
Evidence supporting the view that NF-κB plays a central role as a regulatory target for PD therapy comes from studies using specific NF-κB inhibitors such as pioglitazone (a PPAR-gamma agonist) or curcumin in murine models of PD to show that the administration of these inhibitors could halt the progression of neurodegeneration induced by the neurotoxin, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [8] or by activation of CNS inflammation by the intracranial injection of LPS [9]. Our studies with HE have also clearly demonstrated that administration of HE to α-syn-transgenic mice, significantly decreased the elevated levels of phosphorylated NF-κB in the neocortex of these mice to the low levels observed in the non-transgenic mice [10]. The inhibition of NF-κB activation by HE led to significant inhibition of the production by microglia cells, of the pro-inflammatory cytokines, TNF-α, IL-1β and IL-6, as well as improvement in their locomotor function compared with untreated transgenic control mice [10]. Elevated levels of all of these pro-inflammatory cytokines have been found in the brains, CSF and plasma of PD patients [11].

Nrf2/ARE, PD and HE
Nuclear factor E2-related factor 2 (Nrf2) is a master regulator that induces a battery of cytoprotective genes including antioxidative enzymes, anti-inflammatory mediators, the proteasome, and several transcription factors involved in mitochondrial biogenesis [12].

In pathology of neurodegenerative disorders such as PD, the generation of reactive oxygen species (ROS) may be harmful affecting proteins, lipids and nucleic acids [13].

The Nrf2 pathway is one of the pathways that respond to ROS by activating the transcription of phase II detoxification enzymes [14]. When redox balance is tipped toward the oxidative side, Nrf2 trans-locates into the nucleus and activates the transcription of anti-oxidant response element (ARE)-dependent genes [15]. In regard to PD, one line of evidence suggests the involvement of the Nrf2/ARE pathway in PD’s pathogenesis and that is the localization of Nrf2 in susceptible neuron populations in PD brain tissues from a postmortem study [16]. It was shown that in neurodegenerative diseases, Nrf2 expression is altered in neurons and astrocytes. Nrf2 was activated in SN in PD brains even though the response appeared insufficient to protect neurons from degeneration. However, in Nrf2-deficient mice, dopaminergic neurodegeneration and microglial activation induced by chronic injection of MPTP were more severe than in wild-type mice [17]. Studies demonstrating the Nrf2-activating effects of PD drugs such as apomorphine (Apo) support the link between the Nrf2/ARE pathway and PD. Apo is a drug used for clinical therapy of PD. Apo is a dopamine receptor agonist and has scavenger and protective effects in ROS-induced cell death. Thus, Apo acts by producing intracellular ROS and activating the Nrf2 pathway to promote neuroprotective effects [18].

In studies unrelated to PD, HE was shown to be a potent activator of the Nrf2 signaling pathway, and even 5 times more potent than curcumin in activating Nrf2 target genes [19]. It was demonstrated that the α-β unsaturated carbonyl functional group on HE was essential for Nrf2 activation [19]. Thus, the ability of HE to activate Nrf2 signaling pathway would help promote its scavenger effects in ROS-induced cell death and neuroprotective effects in PD.

PPAR-γ, PD and HE
Peroxisome proliferator-activated receptor-gamma (PPAR-γ) is a nuclear receptor and ligand-dependent transcription factor, which regulates pathways of inflammation, lipid and carbohydrate metabolism, antioxidant defenses and mitochondrial biogenesis. PD has since been associated with impaired mitochondrial complex I (CI) activity, while several gene defects associated with familial PD involve defects in mitochondrial function, causing an imbalance between mitochondrial biogenesis and removal of dysfunctional mitochondria by autophagy [20]. The inhibitors of CI, MPTP and 1-Methyl-4-phenylpyridinium (MPP+), have widely been used in vivo and in vitro to model PD due to their capacity to produce neurochemical, neurological and pathological changes similar to those observed in PD [21,22]. All of these changes were reversed by pre-treatment with the PPAR-γ agonist, rosiglitazone that increased mitochondrial biogenesis, increased oxygen consumption and suppressed free radical generation and autophagy. Thus, rosiglitazone is neuroprotective in PD through a direct effect on mitochondrial function.

Similar to rosiglitazone, HE has also been reported to be a PPAR-γ agonist [23]. Thus, we theorized that the activation of PPAR-γ would lead to multiple levels of protection (increased autophagy, oxygen consumption, mitochondrial biogenesis, SOD, and catalase) [23].

α-Synuclein, PD and HE
PD is characterized by the loss of dopaminergic neurons in the SN and the formation of intraneuronal inclusions called Lewy bodies, which are composed mainly of α-synuclein. Studies have convincingly demonstrated that abnormal deposition of α-synuclein is not only pathological but also critical to the onset and progression of PD [24].

The involvement of α-synuclein in neurodegenerative processes also raises the prospect of new therapeutic strategies that, by counteracting protein accumulation and toxicity, would slow down or halt disease progression. Indeed, administration of HE was shown in α-syn transgenic mice to inhibit the aggregation and reduce the accumulation/deposition of α-synuclein in neurons and the neuropil, which were correlated with the behavioral improvements observed in the mice [10].

Conclusion
Our on-going research and development of Hypoestoxide as a therapeutic agent for PD is primarily based on the four molecular targets described here. For any potential anti-PD drug to be highly effective, it must be able to target these four molecules (NF-κB, Nrf2/ARE, PPAR-γ and α-Synuclein) and of course, most importantly, to cross the blood-brain-barrier and be safe for chronic use. Preliminary toxicology studies in rats and dogs showed that HE was very safe and orally bioavailable.
References

© 2023 Emmanuel A. Ojo-Amaize, et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License